Pluristem's President & CEO to be Keynote Speaker at The 4th Annual Stem Cells Asia Congress

Business Wire, June 23, 2008

NEW YORK -- Pluristem Therapeutics Inc. (NASDAQ: PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that Mr. Zami Aberman, Pluristem's President & CEO, will be the keynote speaker at the 4th Annual Stem Cells Asia Congress held in Singapore, June 25-26, 2008. Mr. Aberman will present on June 26 at 3:05 pm. The title of the presentation is: "Novel Allogeneic Cell Therapy using PLacental eXpanded (PLX) Mesenchymal Stromal Cells, Grown in a 3D Culture."

Mr. Zami Aberman, Pluristem's President & CEO, stated: "We are very pleased to have been invited to present at the 4th Annual Stem Cells Asia Congress and awarded the distinguished role of Keynote Speaker. We believe this invitation reflects the position of Pluristem as a worldwide leader of the allogeneic (non-personalized) cell therapy approach, providing cutting-edge technology and products. We will continue our efforts, utilizing Pluristem's proprietary 3D expansion process, to develop solutions for a variety of indications."

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; PLX-STROKE, targeting ischemic stroke; PLX-MS, targeting Multiple Sclerosis; and PLX-IBD, targeting Inflammatory Bowel Disease (IBD), which includes Crohn's disease and Ulcerative Colitis.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

See our product animation on YouTube:

http://www.youtube.com/watch?v=OFhWXyJT6Us.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that we will continue our efforts, utilizing Pluristem's proprietary 3D expansion process, to develop solutions for a variety of indications, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.